Diagnostic technology company Owlstone Medical has raised $27 million (£22m) in Series E financing to advance its breath-based testing platform for early disease detection, with particular focus on lung cancer, liver disease, and digestive disorders.
Researchers have developed a highly accurate blood test for amyotrophic lateral sclerosis (ALS), potentially reducing diagnosis times and improving patient outcomes.
Beukenlaan 137
5616 VD Eindhoven
The Netherlands
+31 85064 55 82
info@interhospi.com
PanGlobal Media IS not responsible for any error or omission that might occur in the electronic display of product or company data.
